JACC Journals
Aug 24, 2026, 16:38
PCSK9i Is a Powerful Lipid-Lowering Strategy – But Is It Also Anti-Inflammatory?- JACC Journals
JACC Journals shared a post on X about a recent article by Deng Bing-yan et al., published in JACC: Asia, adding:
“PCSK9i is a powerful lipid-lowering strategy – but is it also anti-inflammatory?
JACC: Asia review distinguishes mechanistic signals from proven human effects, showing plaque stabilization, immune pathways and limits of conventional inflammatory biomarkers.”
Title: The Impact of PCSK9 Inhibitors on Circulatory Inflammation: Mechanisms, Evidence, and Application Prospects
Authors: Deng Bing-yan, Wang Jing-ya, Yuan Yu-juan, Dong Xiang-yu, Lai Hong-mei, Peng Hui, Yang Yi-ning, Yu Xiao-lin
Stay updated on the latest scientific advances with Hemostasis Today.
-
Aug 24, 2026, 18:13Chokri Ben Lamine: Ruxolitinib – Comprehensive Clinical Reference
-
Aug 24, 2026, 18:10Yazan Abou-Ismail: ClotCast Episode 8 – What Are Platelets?
-
Aug 24, 2026, 17:11Kristin Neves: Which Hematologic Parameters Guide Your PV Treatment Decisions?
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada
-
Aug 24, 2026, 16:52Davide Capodanno: 10 Trials to Watch at the ESC Hot Lines
-
Aug 24, 2026, 16:48Mohd Ashhad: The Science Behind a Safe Transfusion
-
Aug 24, 2026, 16:36Alejandro González Veliz։ Does ACC/AHA Lesion Complexity Still Matter?
-
Aug 24, 2026, 16:21Kamlesh Darji: Paraneoplastic Syndromes – Tumor with or without Mediator
-
Aug 24, 2026, 15:15Jim Hoffman: Could Targeting NETosis Reduce Long-Term Risk After STEMI?